A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid«) Regimen or A Sequential Azacitidine (Vidaza«) plus Lenalidomide (Revlimid«) Regimen Versus Azacitidine (Vidaza«) Regimen for Therapy of Older Subjects with
This is a clinical trial of investigational drugs lenalidomide (Revlimid«) that will be administered by mouth and azacitidine (Vidaza«) which will be administered by injection.
IRB Protocol #
HEAGIE LEE at -- or HEA.LEE@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. The treatment period can last up to 48 months. The follow up period will consist of phone contact once a month for a minimum of 4 years. // Eligibility includes but is not limited to 65 years or older with acute myeloid leukemia (AML).Eligibility includes but is not limited to 65 years or older with acute myeloid leukemia (AML).